- Home
- LEV vs IMAB Comparison
LEV vs IMAB Comparison
Compare LEV & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEV
- IMAB
- Stock Information
- Founded
- LEV 2011
- IMAB 2014
- Country
- LEV Canada
- IMAB United States
- Employees
- LEV N/A
- IMAB N/A
- Industry
- LEV Auto Manufacturing
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LEV Consumer Discretionary
- IMAB Health Care
- Exchange
- LEV Nasdaq
- IMAB Nasdaq
- Market Cap
- LEV 76.0M
- IMAB 83.8M
- IPO Year
- LEV N/A
- IMAB 2020
- Fundamental
- Price
- LEV $0.21
- IMAB $0.91
- Analyst Decision
- LEV Buy
- IMAB Strong Buy
- Analyst Count
- LEV 4
- IMAB 3
- Target Price
- LEV $1.15
- IMAB $8.00
- AVG Volume (30 Days)
- LEV 919.1K
- IMAB 392.0K
- Earning Date
- LEV 11-06-2024
- IMAB 08-28-2024
- Dividend Yield
- LEV N/A
- IMAB N/A
- EPS Growth
- LEV N/A
- IMAB N/A
- EPS
- LEV N/A
- IMAB N/A
- Revenue
- LEV $176,812,259.00
- IMAB $3,313,984.00
- Revenue This Year
- LEV N/A
- IMAB N/A
- Revenue Next Year
- LEV $68.85
- IMAB N/A
- P/E Ratio
- LEV N/A
- IMAB N/A
- Revenue Growth
- LEV N/A
- IMAB N/A
- 52 Week Low
- LEV $0.18
- IMAB $0.90
- 52 Week High
- LEV $1.99
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- LEV 22.89
- IMAB 34.11
- Support Level
- LEV $0.32
- IMAB $0.90
- Resistance Level
- LEV $0.62
- IMAB $1.00
- Average True Range (ATR)
- LEV 0.05
- IMAB 0.07
- MACD
- LEV -0.02
- IMAB -0.01
- Stochastic Oscillator
- LEV 9.99
- IMAB 17.51
About LEV The Lion Electric Company
The Lion Electric Co. includes designing, developing, manufacturing and distributing purpose-built all-electric medium and heavy-duty urban vehicles including battery systems, chassis, bus bodies and truck cabins. The Group also distributes truck and bus parts and accessories. The Group has one reportable operating segment, the manufacturing and sales of electric vehicles in Canada and in the United States. Geographically, the majority of revenue is generated from Canada.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).